Nicast focuses on biomedical applications like vascular grafts, stent grafts, and coated stents (with or without pharmaceuticals), using its proprietary electrospinning technological platform. Nicast's first application, an artificial peripheral vascular graft, is in pre-clinical studies. The graft's mechanical and in vivo (animal study) performance indicates significant advantages over competing products. Electrospinning technology enables a generation of artificial implants that are stronger than current products and can be produced in complex shapes and homogeneous structures. The technology significantly reduces obstruction rates compared with competing devices now on the market.
Website: www.nicast.com
Website: www.nicast.com
Investors 1
| Date | Name | Website |
| - | Infinity G... | infinity-e... |
Mentions in press and media 1
| Date | Title | Description |
| 13.02.2020 | Interested in Investing in Early Stage Firms? OurCrowd Has a Long List, Reports 36 Exits to Date | OurCrowd is arguably the leading investment crowdfunding platform in the world. Based in Israel but listing offerings from companies around the world, OurCrowd has seen approximately $1.4 billion in committed funding since inception. Of the... |